NCT04188730View on ClinicalTrials.gov

A Study Evaluating the Relative Bioavailability of Lofexidine Granules for Reconstitution Compared to LUCEMYRA (Lofexidine) Tablets and the Effect of Food on the Bioavailability of the Lofexidine Granules for Reconstitution

PHASE1CompletedINTERVENTIONAL
Enrollment

16

Participants

Timeline

Start Date

February 16, 2021

Primary Completion Date

March 26, 2021

Study Completion Date

March 26, 2021

Conditions
Normal Healthy Volunteers
Interventions
DRUG

Lofexidine (granules for reconstitution)

All subjects will be administered one 0.36 mg dose of lofexidine granules for reconstitution.

DRUG

LUCEMYRA (lofexidine) tablets

All subjects will be administered one 0.36 mg dose of LUCEMYRA (lofexidine) tablets.

Trial Locations (1)

89121

Novum Pharmaceutical Research Services, Las Vegas

All Listed Sponsors
collaborator

National Institute on Drug Abuse (NIDA)

NIH

lead

USWM, LLC (dba US WorldMeds)

INDUSTRY

NCT04188730 - A Study Evaluating the Relative Bioavailability of Lofexidine Granules for Reconstitution Compared to LUCEMYRA (Lofexidine) Tablets and the Effect of Food on the Bioavailability of the Lofexidine Granules for Reconstitution | Biotech Hunter | Biotech Hunter